Neuberger High Yield Strategies Fund Inc. (NHS)

Neuberger High Yield Strategies Fund is a closed-end mutual fund. That is a specific thing, and it is different from the mutual funds most people know. An ordinary open-ended mutual fund (a traditional mutual fund) accepts new investor money whenever someone wants to buy in and pays out whoever wants to leave. A closed-end fund is different: it issues a fixed number of shares at an initial public offering, and after that, the number of shares is fixed. If you want to buy shares, you buy them from another investor on the stock exchange, not from the fund itself. If you want to sell, you sell to another investor, not back to the fund. The price you pay depends on what the market is willing to pay, not on the underlying value of the fund’s portfolio. This simple structural difference creates a lot of quirky behaviour.

NHS invests in high-yield bonds and loans. High-yield is a polite term; traders call these junk bonds. A bond is a debt security—essentially an IOU. When a company borrows money, it can borrow from a bank in the form of a loan, or it can issue bonds that investors buy directly. A high-yield bond is issued by a company with a credit rating below investment grade—meaning the company is judged to have a material risk of defaulting on its debt. The bond pays a high interest rate to compensate investors for that risk. If the company survives and pays the bond off, you pocket the interest. If the company goes bankrupt, you lose money.

NHS’s mission is to put money into a portfolio of these high-yield bonds and loans, collect the interest and principal repayments, and distribute the income to shareholders. The fund also attempts to capture capital gains if bond prices rise (which happens when credit conditions improve or when yields fall across the market). At least eighty percent of the fund’s assets must be in high-yield securities, a requirement that locks in the fund’s focus.

How it generates returns

The fund produces returns in two ways. First, interest income: as the companies and loans in the portfolio pay interest, that cash flows into the fund. The fund is typically structured to distribute most or all of this income to shareholders every quarter or month, in the form of cash distributions. If the portfolio yields eight percent annually (a reasonable estimate for high-yield bonds in normal conditions), the fund distributes roughly that amount to shareholders. For a shareholder, this feels like income—you buy shares at $10 and receive, say, $1.20 per year in distributions, or a 12% yield. That yield sounds appealing, and it is real income, but it carries a hidden cost: it may include a return of your own capital, not just the profit the fund earned.

Second, capital appreciation: if the bonds in the portfolio appreciate in value (because credit spreads narrow or yields fall), the fund’s net asset value rises, and shareholders who own shares at that higher value gain. Conversely, if the bonds depreciate (credit spreads widen, yields rise, or the credit quality of issuers deteriorates), shareholders lose.

The use of leverage

What makes NHS structurally different from a simple bond-fund ETF is that it uses leverage. Leverage means borrowing money to invest more than you actually own. Neuberger, as the fund’s manager, has issued debt (mostly in the form of preferred shares and debt securities placed privately with institutional investors) to raise additional cash beyond the shareholder equity. This borrowed cash is then deployed into high-yield bonds. The effect is to amplify returns if the portfolio appreciates and to amplify losses if the portfolio deteriorates.

Here is a simple example. Suppose you have $100 of shareholder capital and you borrow $40. You now have $140 to invest. If your $140 portfolio earns eight percent return (twelve dollars), your $100 equity now has twelve dollars of gains, an 12% return on the original $100. The borrowed $40 you used had to be paid interest; if the interest rate on borrowing was five percent (two dollars), your net gain is ten dollars, a 10% return. The leverage amplified your return from 8% to 10%. But if the portfolio had declined eight percent (losing 11.2 dollars), your $100 equity would have lost 11.2 dollars, and after paying two dollars in interest on the debt, your net loss would be 13.2 dollars, a 13.2% loss. Leverage amplifies both gains and losses.

Neuberger’s use of leverage is carefully managed and disclosed, but it is a material feature of the fund’s behaviour. When credit markets are calm and spreads (the yield premium that investors demand for taking credit risk) are tight, leverage is benign: you borrow at five percent and invest at eight percent, pocketing the three percent spread. When credit markets are stressed and spreads blow out, leverage becomes dangerous: widening spreads can erase the returns high-yield bonds offer, and the leverage amplifies those losses.

Performance in the context of the bond market

NHS’s returns are driven almost entirely by the health of the high-yield credit market. The fund does not pick security by security; that is Neuberger’s job as the portfolio manager. The fund simply holds a portfolio of these securities and passes returns through to shareholders. In quarters where credit is strong and spreads tighten, NHS tends to perform well. In quarters where credit is weak and spreads widen, it tends to underperform or lose money.

The high-yield credit market is cyclical and driven by economic conditions, corporate earnings, and investor risk appetite. When the economy is strong, companies earn more cash and are less likely to default, so their bonds rise in value and yield spreads tighten. When the economy is weak or recession looms, default risk rises and spreads widen, causing bond prices to fall. Investors fleeing credit risk sell first and ask questions later, which can trigger sharp declines in high-yield bonds even before any defaults actually occur.

Closed-end fund mechanics and the discount

The crucial feature that makes NHS different from an open-ended fund or an ETF is the closed-end structure. The fund has a fixed number of shares. The net asset value (NAV) of the fund is the total market value of the bonds in the portfolio, divided by the number of shares. If that bond portfolio is worth $1,100 and there are 100 shares, the NAV per share is $11. But the market price of a share of NHS is set by buyers and sellers on the exchange. If investors are enthusiastic about high-yield bonds, they might bid the share price up to $11.50. If investors are fearful, they might bid it down to $10.50. When the market price is below the NAV, the fund trades at a discount. When it is above, it trades at a premium.

A discount means you can buy $11 of underlying bonds for $10.50. That is attractive. But discounts exist because investors have no way to force the fund to liquidate and pay them out (the fund is closed-end, remember). A discount is a vote of no-confidence by the market, and it can persist or widen if sentiment turns negative. Conversely, a premium means you are paying more than the NAV for the privilege of owning the fund, a feature that makes premiums less attractive for new buyers.

NHS, like most closed-end funds, has often traded at a discount to its NAV. That discount is an economic reality that shareholders must account for. It means that your actual return includes not just the performance of the underlying portfolio but also any change in the discount or premium. If you buy at a 10% discount and the discount persists, you earn the portfolio’s return minus whatever dividend yield the premium erodes. If the discount narrows, you get a gain from that compression.

Who holds NHS and why

NHS shareholders are typically individual investors seeking high current income and those who believe high-yield credit is attractive and underpriced. Retirees seeking to distribute capital and income have historically been significant investors in closed-end funds, because the monthly or quarterly distributions feel like a pension. The fund’s marketing often emphasises the yield, which attracts income-hungry investors even though that yield may include return of capital. Professional investors and traders also own NHS as a position in their portfolio, either as a long bet on high-yield credit or as a convenient vehicle to gain exposure without holding a basket of individual bonds.

The risk for all shareholders is straightforward: a deterioration in the creditworthiness of the borrowers in the portfolio. If economic conditions weaken, corporate earnings fall, and default rates rise, the bonds lose value and the fund’s NAV falls. Distributions may be cut, the discount may widen, and shareholders experience losses. The leverage amplifies these losses. For income investors relying on NHS distributions to fund living expenses, a credit shock can be painful and disruptive.

How to think about NHS as an investment

NHS is not a growth investment; it is an income and credit-risk investment. You buy it because you expect to receive distributions and because you believe high-yield bonds will appreciate over your holding period. You avoid it if you think credit conditions are about to deteriorate or if you need capital preservation. The fund’s yield—currently around 14-15%—is eye-catching but should be scrutinised carefully. Some of that yield is genuine interest income from the bonds; some may be return of capital, a return of your own money. Distributions above the fund’s current yield are unsustainable and eventually erode the NAV. The fund’s track record—its historical returns net of fees and leverage costs—is the best evidence of what returns are realistic. And the discount or premium at which the fund trades is a third variable: buy at a discount if you believe the market is too pessimistic, but recognise that discounts can widen, creating paper losses even if the underlying portfolio is sound.